试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-29
Topical 0.01% Atropine for the Control of Fast Progressing Myopia
编号:NCT04173780登记状态:提前终止企业 / 申办者:University Hospital, Strasbourg, France
药物 / 成分:Atropine 0.01%、Placebo
登记的停止原因(原文):recruitment difficulties
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-29
Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)
编号:NCT04475549登记状态:提前终止企业 / 申办者:Tisento Therapeutics
药物 / 成分:IW-6463 Tablets
登记的停止原因(原文):Study terminated due to enrollment challenges.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-29
Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19
编号:NCT04614025登记状态:提前终止企业 / 申办者:Pluristem Ltd.
药物 / 成分:PLX-PAD
登记的停止原因(原文):The decision to bring the Study to early clinical readout came in response to COVID-19's evolution as a disease, and the significant changes in the standard of care, leading to an increase in the severity of conditions of the intubated patients.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-29
A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer
编号:NCT05966584登记状态:提前终止企业 / 申办者:Memorial Sloan Kettering Cancer Center
药物 / 成分:Benralizumab、fulvestrant or AIs) and PI3K inhibition (alpelisib)
登记的停止原因(原文):Limited amount of eligible participants
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-28
Anesthesia in Patients With Mitochondrial Disease
编号:NCT02053766登记状态:提前终止企业 / 申办者:The University of Texas Health Science Center, Houston
药物 / 成分:Sevoflurane、Dexmedetomidine、Propofol
登记的停止原因(原文):due to covid-19 we were not on track with enrollment rate
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-28
Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer
编号:NCT02875613登记状态:提前终止企业 / 申办者:Assuntina Sacco, M.D.
药物 / 成分:Avelumab
登记的停止原因(原文):Slow patient accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-28
Is There an Interest in Repeating the Vaginal Administration of Dinoprostone (Propess®), to Promote Induction of Labor of Pregnant Women at Term?
编号:NCT02888041登记状态:提前终止企业 / 申办者:University Hospital, Limoges
药物 / 成分:Dinoprostone、Oxytocine
登记的停止原因(原文):Not enough patients
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-28
Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer
编号:NCT03056638登记状态:提前终止企业 / 申办者:Memorial Sloan Kettering Cancer Center
药物 / 成分:Degarelix、stereotactic body radiosurgery (SBRT)
登记的停止原因(原文):Due to low accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-28
Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant
编号:NCT03960008登记状态:提前终止企业 / 申办者:Lahey Clinic
药物 / 成分:Stereotactic Body Radiation Therapy (SBRT)、Trans-Arterial Chemoembolization (TACE)、Doxorubin
登记的停止原因(原文):This study was closed early due to lack of enrollments and insufficient funding.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-28
Convalescent Plasma for Early Treatment of COVID-19
编号:NCT04390503登记状态:提前终止企业 / 申办者:Andrew Eisenberger
药物 / 成分:Convalescent Plasma (anti-SARS-CoV-2 plasma)、Control (albumin 5%)
登记的停止原因(原文):Enrollment challenges
查看官方原始记录 ↗